Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

Big Danish drugmaker Novo Nordisk (NYSE: NVO) reported its third-quarter results on Wednesday, Nov. 5. Although sales and earnings grew year over year, the company downgraded its full-year outlook for the fourth time. Novo Nordisk now expects full-year 2025 sales growth of between 8% and 11% at constant exchange rates. It looks for operating profits to grow between 4% and 7% on a constant-currency basis. Previously, the pharmaceutical giant projected sales growth in the range of 8% to 14%, with operating profit growth of 10% to 16%. Is something rotten in Denmark? Here's what investors need to know.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool